Protagonist Therapeutics, Inc. (Protagonist) has reported positive topline results from the phase 2b FRONTIER 1 clinical trial of JNJ-2113, an oral IL-23R antagonist, i

During the 25th World Congress of Dermatology (WCD), Boehringer Ingelheim presented groundbreaking findings from their EFFISAYIL 2 trial, demonstrating that spesolimab

Positive results from the TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) significantly improved progression-free survival (PFS) compared to doc

SK bioscience and Sanofi's vaccine candidate, GBP410, showed positive results in infant phase II trials. The 21-valent pneumococcal conjugate vaccine combines proteins

The phase 2b study, known as STREAM-AD, met its primary endpoint by evaluating amlitelimab's efficacy in adults with moderate-to-severe atopic dermatitis unresponsive t

Curasight A/S reports positive results from an investigator-initiated phase II study using uPAR-PET (uTRACE) in primary brain cancer. The trial assessed 68Ga-NOTA-AE105

Bayer AG and BlueRock Therapeutics LP announced positive top-line results from a phase I clinical trial of bemdaneprocel (BRT-DA01), an investigational cell therapy for

Aldeyra Therapeutics, Inc. (Aldeyra) announced positive results from the phase 3 INVIGORATE-2 trial of reproxalap, an investigational drug for allergic conjunctivitis.

AbbVie and Genmab reported positive outcomes from the follicular lymphoma (FL) segment of the EPCORE NHL-1 clinical trial. The trial evaluated epcoritamab (DuoBody-CD3x

Astellas Pharma Inc. reported positive results from the phase 3b DAYLIGHT trial for fezolinetant, an investigational nonhormonal compound for treating moderate to sever

GSK plc shared new data from the AReSVi-006 phase III trial, assessing Arexvy (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 years and older. Resul

Escient Pharmaceuticals reported positive results from a phase 1 study of EP262, a selective small molecule antagonist of MRGPRX2. EP262 can potentially treat mast cell

Merck (known as MSD outside the US and Canada) released initial findings from the phase 3 KEYNOTE-585 trial. The study examined Keytruda, Merck's anti-PD-1 therapy, com

Bavarian Nordic A/S, an integrated vaccines company, announced positive initial results from a phase 3 clinical trial of their chikungunya virus (CHIKV) vaccine candida

Allgenesis Biotherapeutics Inc. announced the topline data from their phase 1b clinical trial for AG-80308, a novel ophthalmic drug aimed at treating dry eye disease (D

CorFlow Therapeutics AG has announced positive interim results from the MOCA I study at EuroPCR in Paris. The study evaluates the safety and feasibility of a real-time

Bristol Myers Squibb has released positive results from a phase 2 study on BMS-986278, an oral lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idio

Abbott unveiled significant findings from the AVEIR dual-chamber (DR) i2i Investigational Device Exemption (IDE) study, showcasing the world's first dual-chamber leadle

BioInvent International AB and Transgene have reported positive Phase 1a results for the oncolytic virus BT-001 in treating solid tumours. In a trial involving 18 patie

HanAll Biopharma Co., Ltd. has announced the phase III VELOS-3 trial results evaluating tanfanercept, a novel topical anti-inflammatory treatment for moderate to severe

Lotus Clinical Research, a scientific and consultative CRO, has partnered with Trialogics to strengthen their relationship and expand Lotus' use of Trialogics' clinical

Astellas Pharma Inc. and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) shared findings from the phase 3 MORPHO clinical trial at the 2023 European H

New data from the HARMONIE phase 3b clinical trial shows an 83.21% reduction in hospitalizations due to RSV-related LRTD in infants under 12 months who received a singl

Innovent Biologics, Inc. announced positive results from a phase 2 clinical study of mazdutide (IBI362) in Chinese adults with obesity. The randomized, double-blind, pl

Novavax, Inc. announced positive findings for its Covid-Influenza Combination (CIC) vaccine, stand-alone influenza vaccine, and high-dose Covid vaccine candidates. The

AllgenesisBiotherapeutics Inc., a clinical-stage speciality pharmaceutical company, has announced exciting preliminary data from the initial cohorts of the ongoing phas

AnaMar, a clinical-stage biotech company, reports positive phase I results and completion of phase II for its orphan indication in systemic sclerosis (SSc) with lung an

The FDA has released draft guidance on good clinical practices (GCPs) to modernize clinical trials while maintaining data integrity and participant protections. The rec

Positive results from AstraZeneca's ADAURA phase III trial demonstrated that Tagrisso (osimertinib) significantly improved overall survival (OS) in early-stage (IB, II,

Cactus Communications, a science communication and technology company, has unveiled the Researcher.Life 'All Access Pack', a comprehensive suite of AI tools and service

Pfizer Inc. has received approval from the US Food and Drug Administration (FDA) for Prevnar 20, a vaccine designed to prevent invasive pneumococcal disease (IPD) and o

Starting from 1 June 2023, users logging in to CTIS (Clinical Trials Information System), including both sponsors and Member States, will need to employ multi-factor au

Alentis Therapeutics, a biotech firm specializing in treating organ fibrosis and CLDN1+ tumours, has revealed the results of the multiple-ascending dose (MAD) portion o

Novartis has disclosed the findings of the phase III APPOINT-PNH study, which investigated the use of the oral monotherapy iptacopan in adults with paroxysmal nocturnal

Astellas Pharma Inc. and Pfizer Inc. have announced results from their phase 3 EMBARK trial, which showed that the combination of Xtandi (enzalutamide) and leuprolide r

Glaukos Corporation, a pharmaceutical and ophthalmic medical technology company, has received notification from the US Food and Drug Administration (FDA) acknowledging

FibroGen, Inc. reported that its phase 3 clinical trial, MATTERHORN, evaluating roxadustat for treating anaemia in transfusion-dependent lower-risk myelodysplastic synd

Soligenix, a late-stage biopharmaceutical company, announced positive results from a compatibility study evaluating HyBryte in treating cutaneous T-cell lymphoma (CTCL)

The US FDA has released a draft guidance supporting decentralized clinical trials (DCTs) for medical product development and research. DCTs allow some or all trial-rela

The European Medicines Agency (EMA) is seeking feedback on transparency regulations for disclosing clinical trial information through the EU's Clinical Trials Informati

AstraZeneca and Ionis have reported positive results from the NEURO-TTRansform phase III trial, which evaluated the efficacy and safety of eplontersen in subjects with

AbbVie's atogepant has shown positive results in the phase 3 ELEVATE study for the preventive treatment of episodic migraine in adults who have failed two to four class

IDEAYA Biosciences, Inc. has reported positive interim results from its phase 2 clinical trial on the combination of darovasertib and crizotinib for metastatic uveal me

Actinium Pharmaceuticals has reported positive results from its phase 3 SIERRA, randomized, multicenter, controlled trial of Iomab-B for treating acute myeloid leukaemi

Moderna and Merck have announced that their mRNA cancer vaccine, mRNA-4157/V940, in combination with Merck's anti-PD-1 therapy Keytruda, has received Priority Medicines

The (NEJM) New England Journal of Medicine recently published a study that showed Doxycycline, an oral antibiotic, was found to prevent the acquisition of STIs (sexuall

BenevolentAI, a clinical-stage drug discovery and development company utilizing AI technology, has released top-line findings from its phase IIa study on BEN-2293, a to

Merck, also known as MSD, has provided updates on two phase 3 clinical trials, LEAP-003 and LEAP-017, which focus on investigating the effectiveness of Keytruda, Merck'

BenevolentAI, a clinical-stage drug discovery and development company specializing in AI-enabled solutions, has released top-line results from its recent phase IIa tria

A clinical trial conducted the NIH Clinical Center and the National Institute of Dental and Craniofacial Research (NIDCR) found that denosumab, a medication used to tre

Aurinia Pharmaceuticals announced promising results from the AURORA Renal Biopsy Sub-Study evaluating Lupkynis, a novel agent approved for treating active lupus nephrit

A clinical trial led by the National Institutes of Health (NIH) found that patients with low-grade lymphomatoid granulomatosis treated with interferon alfa-2b can survi

Pfizer recently shared trial results for its experimental respiratory syncytial virus (RSV) vaccine, which apex health regulators are presently reviewing in the US and

Novartis has reported positive results from the phase III trial, NATALEE, evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in subjects with hormone receptor-

Bristol Myers Squibb has received a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) of the EMA (European Medicines Agency) for Breyanzi

The Medicines and Healthcare products Regulatory Agency (MHRA) is set to introduce a range of measures to facilitate faster and easier clinical trial approval in the UK

The Paediatric Artificial Pancreas (PEDAP) Trial conducted in the United States showed that artificial pancreas technology significantly improved blood glucose control

Astellas Pharma Inc. has reported positive topline results from its phase 3 China ARCHES study of Xtandi (enzalutamide) in combination with androgen deprivation therapy

In a recent announcement, InDex Pharmaceuticals Holding AB (publ) revealed that they had conducted a pharmacokinetic (PK) study on cobitolimod, and the results were pos

GSK plc has announced positive headline outcomes from the phase III trial evaluating the tolerability, safety, and immunogenicity of the company's MenABCWY combination

Bristol Myers Squibb and 2seventy bio, Inc. reported the first publication and presentation of positive outcomes from KarMMa-3, open-label, pivotal phase 3, randomized,

Inovio announced positive preliminary results from the second cohort of its phase 1/2 2 open-label, multicenter clinical trial assessing INO-3107 for treating HPV 6 and

Pfizer announced positive outcomes from the phase 3 TALAPRO-2 trial of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor and Xtandi (enzalutam

Merck announced outcomes from the pivotal phase 3 KEYNOTE-859 study investigating Merck’s anti-PD-1 therapy, Keytruda, along with fluoropyrimidine- and platinum-c

Signant Health, the market leader in evidence generation for modern clinical trials, announced the ability to produce computerized adaptive tests (CATs) in clinical tri

Thermo Fisher Scientific launched the Bigfoot Spectral Cell Sorter in India. The unique and exceptionally different cell sorting technology is easy to use and provides

Certa Therapeutics (Certa) reported ground-breaking clinical study data for FT011, its novel therapy for treating severe inflammatory and fibrotic diseases.

Chugai Pharmaceutical Co., Ltd. reported positive outcomes from the global randomized, open-label phase III COMMODORE 2 study, assessing the efficacy and safety of crov

Baudax Bio, Inc. announced the successful result of its first interim analysis in a phase II study of BX1000 for neuromuscular blockade (NMB) in individuals undergoing

Boehringer Ingelheim reported that the multicenter, double-blind, randomized, placebo-controlled phase IIbEFFISAYIL 2 trial completed its primary and key secondary resu

Merck, aka MSD outside of the US and Canada, announced positive results from the randomized, double-blind phase 3 KEYNOTE-966 trial(ClinicalTrials.gov, NCT04003636).&nb

Bristol Myers Squibb reported topline results from TRANSCEND CLL 004, a phase 1/2, single-arm, open-label, multicenter trial investigating Breyanzi (lisocabtagene maral

January 31, 2023, onwards, submission of all initial clinical trial applications in the EU (European Union) shall require employing Clinical Trials Information System (

Roche reported that the phase III IMbrave050 global, open-label, multicentre, randomized trial achieved its primary endpoint of RFS (recurrence-free survival) at the pr

Astellas Pharma Inc. presented detailed results from the phase 3 global, double-blind, multi-centre, randomized SPOTLIGHT trial assessing first-line drug zolbetuximab,

Everest Medicines reported top-line outcomes from a double-blind, randomized, placebo-controlled China phase I trial on healthy subjects exhibiting that EVER206 (also k

Moderna, Inc. announced positive top-line data from its double-blind, randomized,placebo-controlled ConquerRSV Phase 3 pivotal efficacy study of mRNA-1345, an investiga

Feinstein Institutes for Medical Research, the home of the research institutions of Northwell Health and the biggest health care provider and private employer in New Yo

Lipella Pharmaceuticals Inc. reported top-line outcomes of the company's recently concluded phase 2a clinical trial assessing the efficacy and safety of its drug candid

Clene Inc. and Clene Nanomedicine Inc. reported topline results from its phase 2 investigational study with CNM-ZnAg, an ionic and patented solution of zinc and silver,

The PEARL, an open-label, randomised, multicentre, global phase III study for AstraZeneca's Imfinzi (durvalumab), did not fulfil statistical significance for the primar

Zymeworks Inc. announced positive topline outcomes from the pivotal phase 2b HERIZON-BTC-01 global, multicenter, open-label, single-arm clinical study investigating zan

Astellas Pharma Inc. reported positive topline outcomes from the global, double-blind, multi-centre, randomized phase 3 GLOW clinical trial evaluating the efficacy and

Initial developments from the TROPIONPanTumor01 first-in-human, two-part, open-label, multicenter phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed promising an

Synaptogenix, Inc. reported topline results from its National Institute of Health (NIH)-sponsored, randomized, double-blind, placebo-controlled phase 2 clinical study o

BioLineRx Ltd. reported results from phase 1/2a, an open-label, multicenter study of intratumoural cancer vaccine candidate AGI-134, developed to assess the safety and

Arcellx, Inc. reported continued robust long-term responses from its CART-ddBCMA phase 1 expansion study in relapsed or refractory multiple myeloma patients, dosing of

UCB reported positive top-line outcomes from two placebo-controlled, randomized, parallel-group, double-blind, multicenter phase 3 clinical trials, BE HEARD I and BE HE

Novartis reported the phase III APPOINT-PNH trial (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 ther

Replimune Group, Inc. reported an initial data snapshot from the first seventy-five (75) patients from the anti-PD1 unsuccessful cutaneous melanoma cohort of the IGNYTE

GSK plc reported fresh 48-week data from the MOMENTUM, a randomised, global, double-blind phase III trial that demonstrated a majority of patients treated with investig

Novartis announced the pivotal phase III PSMAfore open-label, multi-centre, 1:1 randomized trial of Pluvicto (INN: lutetium (177Lu) vipivotide tetraxetan). 

Vaxxinity, Inc. reported that its next-generation UB-612 Covid-19 vaccine, when given as a single heterologous booster dose, provoked potent neutralizing antibodies aga

AnaptysBio, Inc. reported that GSK's RUBY/ENGOT-EN6/GOG3031/NSGO phase 3, two-part global, double-blind, randomised, multicentre study of Jemperli (dostarlimab) plus st

Pocket Naloxone Corp. reported positive outcomes from its human pharmacokinetic (PK) trial of its novel naloxone nasal swab NaxSwab. The study was a crossover, randomiz

Roche reported promising results from the STRONG-HF (Safety, Tolerability and Efficacy of Rapid Optimization of Heart Failure) study in hospitalized acute heart failure

Kyowa Kirin Co., Ltd., reported topline results from an open-label, multicenter, single-arm phase 2 MIRAGE study assessing zandelisib, an orally dispensed investigation

Ipsen reported the phase 3 NAPOLI 3 trial of Onivyde (irinotecan liposome injection) plus five fluorouracil/leucovorin and oxaliplatin (Nalirifox regimen) achieved its

Viz.ai proclaimed new data from a large aortic dissection AI (artificial intelligence) real-world study that supports its artificial intelligence technology's detection

Merck (MSD outside of the US and Canada) reported positive topline outcomes from the pivotal phase III, double-blind, randomized, KEYNOTE-859 trial investigating Keytru

Processa Pharmaceuticals, Inc. declares positive gastric emptying outcomes from its PCS12852 phase 2A trial in moderate to severe gastroparesis patients.

Apeiron Respiratory Therapies GmbH (AResT) reports positive final outcomes from a placebo-controlled, double-blind, dose-escalation phase I clinical study of inhaled al

The Pfizer/BioNTech ‘bivalent’ Covid vaccine targetting both the Original strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 sub-variants received UK MHRA (

Biophytis SA declared the complete results from its phase 2-3 COVA clinical trial evaluating Sarconeos (BIO101) in treating Covid-19-related respiratory failure.

GSK plc reported that DREAMM-3, the phase III open-label, randomised head-on superiority trial of Blenrep (belantamab mafodotin) monotherapy compared to (PomDex) pomali

Rivus Pharmaceuticals Inc. reported topline results from a double-blind, randomized, placebo-controlled phase 2a study assessing the efficacy and safety of HU6, a first-in-class controlled metaboli

Ionis Pharmaceuticals, Inc. reported positive outcomes from the double-blind, randomized, placebo-controlled phase 2b RE-THINC ESRD trial of fesomersen (previously IONIS-FXI-LRx), an investigationa

Bristol Myers Squibb reported the COMMANDS study, a phase 3, an open-label, randomized trial assessing Reblozyl (luspatercept-aamt), completed its primary endpoint, exh

Actinium Pharmaceuticals, Inc. (Actinium or the Company) declared positive top-line outcomes from the pivotal phase 3 trial for its prospective principal product, Iomab

United Therapeutics Corporation reported that an initial analysis of the EXPEDITE study in subjects suffering from WHO (World Health Organization) Group 1 pulmonary art

Novavax, Inc. declared positive outcomes from the phase 1/2 clinical trial of its CIC (Covid-19-influenza combination) vaccine candidate. Data indicated the CIC vaccine

Pfizer Inc. and BioNTech SE reported early data from phase 2 and 3 clinical trials (NCT05472038) assessing the safety, tolerability, and immunogenicity of both organiza

SIFI S.p.A, Italy, a foremost global ophthalmic company, reported positive outcomes from the positive phase 3 study [NCT03274895] of an investigational anti-amoebic polymer, Akantior (polihexanide

GSK plc reported positive headline results of the PERLA phase II trial, which achieved its primary endpoint of objective response rate (ORR) by Response Evaluation Crit

Pfizer Inc. declared positive topline results from the phase 3 TALAPRO-2 study of Talzenna (talazoparib), an oral PARP (poly ADP-ribose polymerase) inhibitor, in combin

Regeneron Pharmaceuticals, Inc. notified the first presentations of detailed positive results from two pivotal trials investigating novel aflibercept 8 mg with 12- and

Zealand Pharma A/S declared positive topline results from the pivotal, randomized, double-blind phase 3 trial of glepaglutide, a long-acting GLP-2 analogue developed fo

Ionis Pharmaceuticals, Inc. announced the topline results from the phase 2b SOLANO study in patients with hypercholesterolemia. The study demonstrated that 60mg of ION4

Sandoz declares further progress on its biosimilar pipeline, with the announcement of positive results from the integrated ROSALIA phase I/III clinical study for its pr

Pfizer released positive top-line results from its pivotal EU phase 3 study in infants (NCT04546425), analyzing its 20vPnC (20-valent pneumococcal conjugate vaccine can

A prespecified interim analysis of the ALPHA phase III trial analyzing danicopan (ALXN2040), oral factor D inhibitor, an investigational, as an add-on to C5 inhibitor t

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. declared positive interim results from an ongoing phase 1 clinical trial of NTLA-2001, in vivo CRISPR/Ca

Amgen submitted new convincing data from the phase 3 FOURIER open-label extension (OLE) studies of Repatha (evolocumab) in adults with atherosclerotic cardiovascular di

Pfizer Inc. reported positive top-line data from the phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV diseas

Amgen declared positive top-line outcomes from the DAHLIA study, a randomized, double-blind, active-controlled, two-period crossover phase 3 study assessing the efficac

Early results from the TROPION-Lung02 phase Ib trial exhibited that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemoth

Endo International plc declared top-line results from its phase 2 study of Collagenase Clostridium histolyticum (CCH) in subjects with adhesive capsulitis (AC) of the s

Biotechnology company, Ocugen Inc., declared the publication of positive pediatric phase 2/3 study results in children aged 2–18 years for the Covid-19 vaccine Co

Intellia Therapeutics Inc. and Regeneron Pharmaceuticals Inc. declared further positive provisional data from an ongoing phase 1 study of their lead investigational in vivo genome editing candidate

Merck (MSD outside the US and Canada) announced positive results from the phase 1/2 study of V116-001, the company’s investigational 21-valent pneumococcal conjug

Ionis Pharmaceuticals Inc. reported positive topline results from a 35-week interim investigation of phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplonters

Teva Pharmaceuticals Europe B.V. reports promising interim results from its PEARL (Pan-European Real World study), presented for the first time at the EAN (European Academy of Neurology) Congress i

AlzeCure Pharma AB (publ) reported completion of clinical phase I study (multiple ascending doses, MAD) with repeated dosing of the drug candidate ACD856 that focuses o

Basilea Pharmaceutica Ltd reported positive topline outcomes for the phase 3 ERADICATE study, assessing ceftobiprole in the treatment of adult patients with bacterial b

The USFDA disapproves plasma therapy as an emergent weapon for treating COVID -19 as reported on 19 August, 2020. However, currently the plasma therapy is being tested globally

FDA registered a non- prescription over the counter ointment possessing virucidal activity has the potential to kill and treat viral infections including SARS-CoV-2, the virus respon

The Drug Controller General of India gave approval to Bharat Biotech to test its first Covid-19 vaccine via the skin through intradermal delivery.  The company would now conduct

Clinical trials are the research-based studies conducted on human volunteers to evaluate a medical and therapeutical intervention by determining its effects in human health outc

A globally active biopharmaceutical company known as Marinomed Biotech AG, located in Vienna, has obtained promising outcomes in preclinical studies for further areas of ap

Less than 8% of people who experience from cardiac arrest outside of the hospital survive the incident, as per the American Heart Association.

To enhance

In a novel retrospective study, researchers discovered that the utilization of immunosuppressive therapy does not enhance the occurrence or recurrence of vulvar or vaginal

Breathing impure air takes a huge toll on gut bacteria, enhancing risk of diabetes, obesity, gastrointestinal disorders and other chronic illnesses, new University of Color

About 30 million people in the U.S. attain criteria for alcohol use disorder, yet less than 1 million get medication that may be useful.

A randomized clin

Advanced prostate cancer etiology is understood very poorly. Few have evaluated the role of early adulthood BMI and adult BMI changes on risk of advanced forms of prostate

The potential utilization of Artificial Intelligence in the field of sleep medicine, leading to advance diagnosis and treatment is administered by a position statement from

A research-based global biopharmaceutical company, AbbVie, declared that the European Commission has granted a change to the marketing authorization for Maviret (glecaprevi

AstraZeneca has Declared that the phase 3 DANUBE clinical trial for Imfinzi plus tremelimumab and Imfinzi (durvalumab) is unblockable, Stage IV (metastatic) bladder cancer

A team of Russian scientists has made chemically manganese-zinc ferrite nanoparticles that can potentially be utilized in cancer treatment. Due to their advance and unique

A clinical stage drug development company known as Dynacure is committed on enhancing the lives of patients with rare and orphan disorders declared that the first patient h

Monoamine oxidase A (MAOA) stimulates prostate cancer growth and metastasis in pre-clinical models. They evaluated the impacts of phenelzine (a monoamine oxidase inhibitor)

Management of chronic constipation is frustrating as patients frequently remain dissatisfied with laxative treatments. Chronic constipation impacts about 15 percent of the

A clinical-stage biopharmaceutical company known as NuCana declared that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has furn

A clinical-stage biopharmaceutical company, Actinium Pharmaceuticals, declared that the 1st patient has initiated treatment in the third and final cohort of the Actimab-A C

The BRCA gene family which is generally known as the breast cancer genes acts in the repairing of damaged DNA. Inherited mutations in the genes BRCA1 or BRCA2 elevate the r

Nemours Children's Health System researchers used Next Generation Sequencing (NGS) to more accurate identification of genomic characteristics of leukemias in children, the

Mice under exposure to stress in the womb and soon after birth can anticipate a lifetime of immune system deficiencies that interferes the ability to ward off infections an

Distraction by technology during mealtimes may lower the amount of food a person eats, nutrition scientists recommended in a new study.

When 119 young adu

While there is a linkage between heart failure and liver fibrosis, the mechanisms for this linkage are presently unclear but may be of particular significance for people li

Researchers from the School of Pharmacy at Queen’s University Belfast (QUB) have created a new antimicrobial coating which can be used to urinary catheters and other medic

Researchers at the National Institutes of Health (NIH) and the University of Wisconsin have showed that using artificial intelligence (AI) to study CT scans can make more accura

UCL and the Imperial College London researchers stated that their proof-of-concept study, advertised today in npj Digital Medicine, makes the way for the development of hig

A psychobiological state known as mental fatigue caused due to extended periods of demanding cognitive activity which leads to slower reaction times and attention deficienc

Tramadol has been suggested as one of the first‐line or second‐line therapies for patients with chronic non-cancer pain by several professional organizations. These involve fibromyal

A world-class biopharmaceutical company known as Innovent Biologics Inc, that develops and commercializes high quality medicines for the treatment of autoimmune, cancer, metabolic an

A clinical stage biotherapeutics company, PureTech Health, focussed on developing, discovering and commercializing highly distinguished medicines for devastating diseases, declared t

In the Journal of Molecular Diagnostics a report appeared by Elsevier detailing a new technique that uses real-time next-generation sequencing (NGS) to analyze tiny amounts of microb

Researchers have discovered that MRI-targeted biopsy can greatly enhance prostate cancer diagnosis and lower the chances of patients being either over treated or undertreat

Antibiotic consumption during the second trimester and infancy could enhance the risk of childhood overweight or obesity, a current meta-analysis advertised in the Journal

An international team of researchers headed by scientists at Baylor College of Medicine has new information into the function of neurofibromin, a tumor suppressor geenrated

A minimal invasive as well as cost-effective blood test has been created by the researches from the National Institute of Ageing here which can diagnose Alzheimer's disease

Researchers have discovered that exposure of people with mild traumatic brain injury to early morning blue light therapy may lower depression and other concussion symptoms.

Stroke is typically caused due to blood clot in the brain and can result in death within minutes. In the UK alone, more than 100,000 strokes occur annually, on an average o

Hyper somnolence is described as excessive daytime sleepiness even after having seven or more hours of sleep. It can be deteriorating for some people, impacting the way tha

A research-based global biopharmaceutical company known as AbbVie has declared the VIALE-C (M16-043) trial of Venclexta (venetoclax) in combination with low-dose cytarabine

A clinical-stage biopharmaceutical company known as IO Biotech is developing novel, immune modulating anti-cancer therapies grounded on its proprietary T-win technology, de

Mobile stroke units well-equipped with CT for prehospital thrombolysis not only lowers the time of treatment, but had higher rates of thrombolysis and decreased risk for di

Intracranial stents safely lowers the risk of recurrence is the observation of WOVEN trial which is one of the largest on-label, intracranial stenting trial to-date with lo

Inserting phone-based lifestyle counseling to home blood pressure tele-monitoring is an impactful strategy to enhance long-term blood pressure control among minority stroke

New research from McMaster Hospital of Children demonstrates that 2 out of 3 young mothers have at least one mental associated health problem.

Researchers

Priorly this year, researchers and doctors celebrated the news that the 5-year survival rate for pancreatic cancer had surpassed into double digits for the first time up fr

The ICH E9(R1) Addendum to describing the proper Estimand for a Clinical Trial / Sensitivity Analyses reached Step 4 of the ICH Process. The topic was sponsored by the ICH

The FDA advertised a new guideline on Adaptive Design Clinical Trials for Drugs and Biologics. The document offers guidance to sponsors on the appropriate usage of adaptive

Maternal obesity may enhance the risk of a child for attention-deficit hyperactivity disorder (ADHD), as per the analysis by researchers from Human Development (NICHD), par

Postanesthetic shivering without severe side effects can be prevented by using ketamine, as per the recent study in the journal BMC Anesthesiology. The study further discov

People with radiographic or symptomatic knee osteoarthritis (OA) are at elevated risk of all‐cause mortality, as per the recent study advertised in the journal Arthritis

HIV-infected patients are at enhanced risk of non-alcoholic steatohepatitis (NASH). Vitamin E is suggested for the treatment of NASH in the general population. However, its

Critically ill patients may benefit from the uptake of vitamin C, a current meta-analysis in the Journal of Intensive Care has indicated. As per the study, vitamin C shorte

Myocardial infarction is a vital form of cardiovascular disease worldwide. Researchers at Yale University have discovered that even a few hours' exposures to ambient ultraf

Early administration of dexamethasone could lower the span of mechanical ventilation and overall death in patients with established moderate-to-severe acute respiratory distress synd

Persistent with antimicrobial stewardship efforts, a current study has discovered that the span of antibiotic treatment for uncomplexed urinary tract infection (UTI) is not

Throughout the United States few drops of blood are accumulated from every newborn which are then preserved on filter paper and analyzed for dozens of genetic and congenita

Overall mental health initiates to decline in Individuals with schizophrenia once the onset of symptoms. This gradual fall often continues for many decades, regardless of w

Erectile dysfunction is a consistent inability to acquire an erection sufficient to allow satisfactory sexual intercourse and is on the elevation globally. It has a negativ

The Indian Drug Manufacturers Association (IDMA) has requested the Drugs Controller General of India (DCGI) seeking registration fees of Rs15,000 to continue instead of Rs.

Researchers from the University of Basel have come to a conclusion that in pediatric age group preventive pharmacological treatment of migraine is no more impactful than pl

Early prevention of menopause can be done by childbearing and breastfeeding as per the finding of one of the largest studies. Description of the study has advertised in the

In a current study, researchers have discovered traces of a disease called as Scurvy in Canada. The deteriorating condition is remembered as a disease of pirates.

A biopharmaceutical company, Kala Pharmaceuticals, Inc., committed on the development and commercialization of therapeutics utilizing its proprietary AMPPLIFY™ mucus-

A research-based global biopharmaceutical company, AbbVie, today declared that SKYRIZI™ attained both primary and all ranked secondary endpoints, involving superiorit

2 years ago the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) enacted a “final rule” clarifying how and when universities, comp

GNT Pharma has successfully done Phase 3 clinical trial for crisdesalazine, a novel drug to treat canine cognitive dysfunction syndrome or Alzheimer’s disease.

The Cure Parkinson’s Trust (CPT) is enthusiastic to declare the publication of the outcomes of a Phase 2 clinical trial examining ambroxol as a potential treatment to decrease

Patients suffering from the inflammatory bowel disease ulcerative colitis have a increased risk of dying from colorectal cancer, despite modern therapeutics, even though the ris

As per the professor Ian Cheeseman from Texas Biomedical Research Institute that they don't know what is inside malaria infections, or how many different genetically distinct st

Ultrasound waves of scaled intensity and frequency have demonstrated hope in breaking apart different types of cancerous cells without harming healthy blood cells.

The w

Merck declared that the phase III KEYNOTE-604 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, in combination with chemotherapy attained one of its dual primary endpo

The blood test, though, was not precise at quantifying patients who did have brain tissue.
A new blood test could precisely quantify elderly concussion patients without brain ti

Sleep duration in children can help in anticipating the future occurrence of psychiatric disorder, a recent study has indicated. Targeting sleep duration thus could be useful fo

A biopharmaceutical company known as Spectrum Pharmaceuticals, Inc. committed on new and innovative and targeted oncology therapies, has reported that its pre-specified primary&

Parkinson’s disease is a neurodegenerative disorder that demonstrates symptoms such as tremor, limb rigidity, slow movements and gait, and balance problems. It impacts about 10

Launched first in 2006, the multi-dose human papillomavirus (HPV) vaccine can prohibit most anal and cervical cancers among children and young adults which came in contact to the vir

A Phase 3 study examining the lumasiran RNAi therapeutic has reached its primary and secondary endpoints. Alnylam Pharmaceuticals, which manufactures the drug, reports that the

Opioid epidemic in developed countries is harmful for both adults and children, and is constricting the respective health care systems. Researchers performed research to illustr

Acupuncture and/or acupressure may lead to vital reductions in the cancer pain intensity, reduction of requirements for opioids for the said purpose, indicates a recent study ad

GSK declared positive headline outcomes for intravenous (IV) Benlysta (belimumab) in the largest controlled phase III study in active lupus nephritis (LN), an inflammation of the kid

A company committed to developing and delivering medicines known as Adamas Pharmaceuticals, Inc., which are involved in making a clinically meaningful difference to people impac

A worldwidel biotechnology company known as BioMarin Pharmaceutical has announced positive final outcomes from its randomized, double-blinded, placebo-controlled phase III 

Topline outcomes were declared by Novartis from its pivotal global phase 3 LUSTER-1 and LUSTER-2 studies traversing the efficacy and safety of the investigational oral, once-dai

Eli Lilly and and Boehringer Ingelheim Company declared outcomes from the EMPERIAL- Reduced and EMPERIAL-Preserved studies associated to functional endpoints with empaglifl

A pioneering medical device company known as Reprieve Cardiovascular is committed on enhancing results for patients suffering from acute decompensated heart failure (ADHF), 

Fergene  declared positive results from the pivotal Phase III clinical trial
accessing nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy, to treat hi

A fully owned subsidiary of Otsuka Pharmaceutical Co. Ltd., known as Astex Pharmaceuticals, Inc., based in Tokyo, Japan has showed topline data from the ASCERTAIN phase III tria

Novartis, declared data from the 52-week pivotal phase 3 PALLADIUM clinical trial which showed that QMF149 is a once-daily fixed-dose combination of indacaterol acetate and mometason

Positive phase III ACHIEVE I trial results were declared by Allergan for ubrogepant (UBR-MD-01), a robust phase III clinical trial examining the safety, efficacy and tolerability of

K-Beauty’s leading skincare company, Dr. Raymond Labs which is committed for development and marketing innovative, affordable clinic-level skincare at home, declared the releas

Together, Pfizer, Inc. and a genomic medicine company, Sangamo Therapeutics, Inc., declared updated follow-up results from the Phase I/II Alta study examining investigational SB-525

Positive top-line results were presented by ACADIA Pharmaceuticals from its Phase III HARMONY study. HARMONY was a phase III study which was
double-blinded, placebo-controlled,

As per the reports submitted at the International Society for Pediatric and Adolescent Diabetes (ISPAD) 45th Annual Conference in Boston, children and adolescents aged between 6 to 1

A clinical-stage biotechnology company known as OSE Immunotherapeutics, declared completion and positive results from the phase I study of OSE-127, a humanized monoclonal antibody wi

Positive results from the phase II LILAC study were declared by Biogen Inc for examining the efficacy and safety of BIIB059, a fully humanized IgG1 monoclonal antibody (mAb) targetin

Roche declared the positive data from SAkuraSky, a pivotal phase 3 study of the investigational medicine satralizumab to treat neuromyelitis optica spectrum disorder (NMOSD).

An unexpected result was published by TauRx which is based in Aberdeen, Scotland and Singapore for the pharmacokinetic analysis of the drug hydromethylthionine (LMTM) in Alzheimer&rs

The ongoing phase 3 ALTA-1L trial of brigatinib (Alunbrig) in comparison to crizotinib (Xalkori) indicated that brigatinib reduced the risk of disease progression or death in adults

A clinical stage immuno-oncology company, known as Medicenna Therapeutics Corp., has submitted updated clinical results from its Phase IIb trial of MDNA55 in patients with recurrent

The US Food and Drug Administration has granted approval to Medtronic for its IN.PACT AV Drug-coated Balloon (DCB) which is a paclitaxel-coated balloon for the treatment of failing A

Mylan Laboratories has been pulled up by the USFDA for violating good manufacturing norms, involving lapses in handling raw materials and issues regarding cleaning of equipment, at i

VistaGen Therapeutics, declared topline results from the ELEVATE study, a phase II study of AV-101, its NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, as an ancillary

A leader in rheumatology and immuno-dermatology, Novartis, proclaimed elaborated results from the phase 3 PREVENT trial, examining the efficacy and safety of Cosentyx (secukinumab) i

AstraZeneca presents elaborated results from the positive phase 3 TULIP 2 trial for anifrolumab, a possible new drug for the treatment of moderate to severe Systemic Lupus Erythemato

Therapix Biosciences Ltd. declared topline results from its Phase IIa clinical study at Assuta Hashalom Medical Center in Israel, recommending that THX- 110, a combination of dronabi

DURECT Corporation, declared the results from its Phase IIa clinical trial of DUR-928 in Alcoholic Hepatitis (AH).

As stated by the principal investigator in the trial, Dr. T

Indalo Therapeutics is involved in discovering and developing integrin antagonists for patients plagued by serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and n

Novartis, declared results from the EXCEED head-to-head trial Cosentyx (secukinumab) comparing to Humira (adalimumab) in patients with active psoriatic arthritis (PsA). While Cosenty

AbbVie, proclaimed positive top-line data from the SELECT-PsA 2 phase III study. In the trial, both the doses of Rinvoq met the primary endpoint of ACR20 response at week 12 in compa

A commercial-stage biopharmaceutical company, Paratek Pharmaceuticals shared the outcome of its two exploratory phase II clinical studies examining the safety and efficacy in patient

Promentis Pharmaceuticals is developing technologically advanced therapies for neuropsychiatric disorders. It has successfully completed a behavioral biomarker study for its lead com

The Therapeutic Goods Administration (TGA),Australia has given the approval to Mallinckrodt Pharmaceuticals, for Uvadex (methoxsalen). The approval is given for extracorporeal admini

A translational medicine company named ORYX focusses on oncolytic virotherapy and cancer vaccines, reported positive clinical trial results from a dose-escalating phase I/IIa trial w

The Indian Pharmacopoeia Commission (IPC) has suggested to pharmacy institutes to mandate use of PvPI-ADR mobile application by the students for reporting Adverse Drug Reactions (ADR

A clinical-stage biopharmaceutical company, MorphoSys AG, proclaimed top line results from the initial analysis of the etrospective observational matched control cohort (Re-MIND). Th

AstraZeneca, proclaimed positive Progression-free Survival (PFS) results for Imfinzi (durvalumab) and tremelimumab, an antibody of anti-CTLA4 when incorporated to chemotherapy, from

Therapix Biosciences Ltd proclaimed positive results in its pre-clinical study evaluating THX-210, a proprietary novel pharmaceutical preparation containing non-psychoactive cannabin

Eli Lilly and Company proclaimed top-line results from its phase III SEQUOIA trial accessing pegilodecakin plus Folfox (folinic acid, 5-FU, oxaliplatin) in comparison to Folfox alone

An approval by FDA has been received for multiple myeloma which is an updated label in breast cancer, a breakthrough therapy designation in prostate cancer, grants awarded for resear

An approval has been given by the U.S. Food and Drug Administration (FDA) for a new medication to treat acute migraine with or without aura called Reyvow. As per its manufacturer, El

Eli Lilly and Company proclaimed that Taltz met co-primary endpoints in paediatric patients with moderate to severe plaque skin problem, demonstrating that 89% of patients treated wi

Incite announced the positive 52-week results from its irregular, double-blind, dose ranging, part two study evaluating ruxolitinib cream, a non-steroidal,&n

The US Food and Drug Administration (FDA) has paved the way for the geko device for stimulation of calf muscles to prevent venous thrombosis in non-surgical patients at risk for veno

Results obtained from a phase III clinical trial distinguishing Keytruda (pembrolizumab) to standard chemotherapy highlights the immunotherapy drug still has a long way to go as a vi

Sosei Group Corporation has made an announcement regarding Novartis by sharing the positive results from its Phase III IRIDIUM trial.

The results demonstrated the combination

Full pivotal phase III study results were presented by Roche for satralizumab as a monotherapy for neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system diseas

An announcement has been made by Chugai Pharmaceutical Co., Ltd., regarding the results from SAkuraStar Study which were demonstrated at the Congress of European Committee for Treatment and Researc

Detailed results from phase III CASPIAN trial were presented by AstraZeneca, demonstrating Imfinzi (durvalumab) significantly enhanced overall survival (OS) in patients with previously-untreated ex

An announcement has been made by Novartis regarding positive data from 5-year open-label treatment period (OLTP) accessing sustained efficacy and long-term safety of Aimovig (erenumab) in patients

Bristol-Myers Squibb Company announced the phase 3 CheckMate -548 trial updates, accessing the addition of Opdivo (nivolumab) to current radiation therapy with temozolomide as compared to alone sta

One of the leading RNAi therapeutics company Alnylam Pharmaceuticals, Inc, provides complete positive results from the ORION-11 phase 3 study of inclisiran, an RNAi therapeutic in development for t

An announcement by Roche regarding the phase III BLOCKSTONE study demonstrated preventive treatment with Xofluza (baloxavir marboxil) after exposure to an infected household member significantly le

An announcement by Novartis has been made regarding positive results for ofatumumab (OMB157) from the phase III ASCLEPIOS I and II studies. In both head-to-head studies, ofatumumab showed superiori

AbbVie has announced regarding MERU, a phase 3 trial accessing Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), showed no survival benefit at a pre-planned int

An announcement has been made by AstraZeneca regarding the phase III TULIP 2 trial for anifrolumab, which is a potential novel medicine for the treatment of systemic lupus erythematosus (SLE), met

An announcement was made by AstraZeneca regarding positive results of phase III ETHOS trial for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with moderate to very seve

An announcement was made by AstraZeneca regarding positive results from phase III ETHOS trial for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with moderate to very se

The Union health ministry is likely to forgo the need of clinical trials conduction in India for European Union (EU) approved medical devices through an amendment of Rule 63(1) under the Medical De

InDex Pharmaceuticals announced positive top line results from the dose optimization study CONDUCT, which is accessing cobitolimod for the treatment of moderate to severe ulcerative colitis. The st

A highly distinguished, multiproduct medical device company, PAVmed Inc., has made an announcement that all 20 patients of its first-in-human (FIH) 510(k) clinical safety study underwent successful

The Indian Pharmacopoeia Commission (IPC) receives 1,213 adverse events related with medical devices since 2014 across the country. IPC is the national coordinating centre to have materiovigilance

The students of Indian Pharmaceutical Association, Delhi branch conducted a survey regarding the indiscriminate antibiotics use. They estimate that around 10 million individuals may lose their live

Positive clinical trial results for MemorEM and Alzheimer’s TEMT trial

Positive results have been announced by NeuroEM Therapeutics fo

The earlier results of an important phase III clinical trial demonstrates that the genetically targeted drug olaparib exceeds positive outcomes for men with advanced prostate cancer whose tumours h

The Pharmacovigilance Programme of India (PvPI) reveals that major suspected adverse drug reactions associated with anti-retroviral drugs such as efavirenz, lamivudine and tenofovir.

PvPI i

Olaparib (Lynparza) showed a statistically major improvement in radiographic progression-free survival (rPFS) compared with enzalutamide (Xtandi) or abiraterone acetate (Zytiga) in men with metasta

The I-SPY 2 TRIAL is a combined effort among academic investigators from 20 prominent cancer research centers across the U.S. and Quantum Leap Healthcare Collaborative, the FDA, and the Foundation

A Swedish biotech company, Cyxone renowned for autoimmune diseases announced that phase I clinical trial of T20K successfully attained its objective of confirming T20K's safety and tolerability in

A biopharmaceutical company, Verona Pharma plc, announces the positive Phase II data for dry powder inhaler (“DPI”) formulation of its lead development product, Ensifentrine. It is mean

Nestle is facing heat following the instructions of the Union Health Ministry to the Indian Council of Medical Research. Nestle was involved in conducting research in Indian hospitals which is agai

Novartis announced that Kisqali (ribociclib) achieved statistically significant improvement in overall survival during phase III MONALEESA-3 clinical trial. This being the second phase III clinical

A phase 3 trial of liver cancer of Transgene and SillaJen’s oncolytic virus has been halted early for futility.

SillaJen designed the 600-subject trial to exhibit whether administerin

Medical device clinical investigation guidance underwent a revision in 2013 by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for reflecting the EU’s medical device

Draft national guidelines for gene therapy development and clinical trials have been placed in public domain by the Union Health Ministry for suggestions from concerned parties like scientists, aca